{
    "eid": "2-s2.0-85158094986",
    "title": "Practical considerations for the use of SGLT-2 inhibitors in the Asia\u2013Pacific countries\u2014An expert consensus statement",
    "cover-date": "2023-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Nephrology",
            "@code": "2727",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "acute kidney injury",
        "chronic kidney disease",
        "ketosis",
        "sodium-glucose transporter 2 inhibitors",
        "urinary tract infections"
    ],
    "authors": [
        "Adrian Liew",
        "Aida Lydia",
        "Bien J. Matawaran",
        "Paweena Susantitaphong",
        "Huong Thi Bich Tran",
        "Lee Ling Lim"
    ],
    "citedby-count": 0,
    "ref-count": 64,
    "ref-list": [
        "Dapagliflozin and cardiovascular outcomes in type 2 diabetes",
        "Canagliflozin and cardiovascular and renal events in type 2 diabetes",
        "Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials",
        "Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)",
        "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy",
        "Different eGFR decline thresholds and renal effects of Canagliflozin: data from the CANVAS program",
        "Relative and absolute risk reductions in cardiovascular and kidney outcomes with Canagliflozin across KDIGO risk categories: findings from the CANVAS program",
        "Cardiovascular outcomes with Ertugliflozin in type 2 diabetes",
        "Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial",
        "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes",
        "Sotagliflozin in patients with diabetes and chronic kidney disease",
        "Dapagliflozin in patients with chronic kidney disease",
        "Empagliflozin in patients with chronic kidney disease",
        "Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial",
        "Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials",
        "Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs",
        "Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER",
        "Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis",
        "Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study",
        "Comprehensive Management of Cardiovascular Risk Factors for adults with type 2 diabetes: a scientific statement from the American Heart Association",
        "The lancet commission on diabetes: using data to transform diabetes care and patient lives",
        "Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice",
        "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL 2 study",
        "Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world)",
        "Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study",
        "Empagliflozin in patients with chronic kidney disease",
        "Executive summary of the KDIGO 2022 clinical practice guideline for diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence",
        "2022 American College of Cardiology/American Heart Association/Heart Failure Society of America guideline for the Management of Heart Failure: executive summary",
        "10. Cardiovascular disease and risk management: standards of medical Care in Diabetes-2022",
        "11. Chronic kidney disease and risk management: standards of medical Care in Diabetes-2022",
        "Cardiovascular and renal outcomes with Empagliflozin in heart failure",
        "Empagliflozin in heart failure with a Preserved ejection fraction",
        "SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis",
        "Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials",
        "Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors",
        "Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials",
        "Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis",
        "Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review",
        "SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials",
        "SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: a pooled analysis examining safety endpoints",
        "Sodium-glucose Cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study",
        "Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes",
        "Sodium-glucose Cotransporter-2 inhibitors and urinary tract infections: a propensity score-matched population-based cohort study. Can",
        "Clinical practice guideline for the Management of Asymptomatic Bacteriuria: 2019 update by the Infectious Diseases Society of America",
        "Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin",
        "Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis",
        "Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis",
        "Genital infections with sodium glucose Cotransporter-2 inhibitors: occurrence and Management in Patients with type 2 diabetes mellitus",
        "Hyperglycemic crises in adult patients with diabetes",
        "Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors",
        "Comparative safety of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis",
        "Newer perspectives of mechanisms for Euglycemic diabetic ketoacidosis",
        "Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors",
        "Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition",
        "Use of SGLT2 inhibitors during Ramadan: an expert panel statement",
        "Treatment options for patients with type 2 diabetes mellitus during the fasting month of Ramadan",
        "Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors: a systematic review and meta-analysis",
        "Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy",
        "Elements for success in managing type 2 diabetes with SGLT-2 inhibitors: individualizing treatment with SGLT-2 inhibitor therapy in type 2 diabetes mellitus",
        "Long-term safety of Dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies",
        "Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial",
        "Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials",
        "Dapagliflozin in patients with heart failure and reduced ejection fraction",
        "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction"
    ],
    "affiliation": [
        {
            "affiliation-city": "Manila",
            "@id": "60071489",
            "affilname": "University of Santo Tomas Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071489",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Central Jakarta",
            "@id": "60069378",
            "affilname": "Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069378",
            "affiliation-country": "Indonesia"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60029157",
            "affilname": "Universiti Malaya",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029157",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60002798",
            "affilname": "Chinese University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "113083378",
            "affilname": "Asia Diabetes Foundation",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113083378",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "112810147",
            "affilname": "Mount Elizabeth Novena Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/112810147",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Ho Chi Minh City",
            "@id": "105305134",
            "affilname": "University of Medicine and Pharmacy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/105305134",
            "affiliation-country": "Viet Nam"
        }
    ],
    "funding": []
}